TP53 silencing bypasses growth arrest of BRAFV600E-induced lung tumor cells in a two-switch model of lung tumorigenesis

Cancer Research

Volumn 75, Issue 15, 2015, Pages 3167-3180

  Shai, Anny ^a   Dankort, David ^a   Juan, Joseph ^a   Green, Shon ^a   McMahon, Martin ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; RECOMBINASE; BENZAMIDE DERIVATIVE; BRAF PROTEIN, HUMAN; DIPHENYLAMINE; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE;

ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CARCINOGENESIS; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CONTROLLED STUDY; EPIGENETICS; EPITHELIUM CELL; G1 PHASE CELL CYCLE CHECKPOINT; GENETIC ANALYSIS; GENETICALLY ENGINEERED MOUSE STRAIN; LUNG ADENOMA; LUNG ALVEOLUS EPITHELIUM; LUNG TUMOR; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; ADENOCARCINOMA; ADENOMA; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CYCLE CHECKPOINT; CELL PROLIFERATION; CELL SURVIVAL; DISEASE MODEL; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; METABOLISM; PATHOLOGY; TRANSGENIC MOUSE;

ADENOCARCINOMA; ADENOMA; ANIMALS; BENZAMIDES; CELL CYCLE CHECKPOINTS; CELL PROLIFERATION; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DIPHENYLAMINE; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; LUNG NEOPLASMS; MAP KINASE KINASE KINASES; MICE, TRANSGENIC; PROTO-ONCOGENE PROTEINS B-RAF; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84941577939     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-3701     Document Type: Article

References (54)

1. Hayat MJ, Howlader N, Reichman ME, Edwards BK. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist 2007;12: 20-37.
2. Imielinski M, Greulich H, Kaplan B, Araujo L, Amann J, Horn L, et al. Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma. J Clin Invest 2014;124: 1582-6.
3. Heist RS, Engelman JA. SnapShot: Non-small cell lung cancer. Cancer Cell 2012;21: 448 e2.
4. Network CGAR. Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014;511: 543-50.
5. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012;2: 401-4.
6. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013;6: Pl1.
7. Fasbender A, Lee JH, Walters RW, Moninger TO, Zabner J, Welsh MJ. Incorporation of adenovirus in calcium phosphate precipitates enhances gene transfer to airway epithelia in vitro and in vivo. J Clin Invest 1998;102: 184-93.
8. Dankort D, Filenova E, Collado M, Serrano M, Jones K, McMahon M. A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes Dev 2007;21: 379-84.
9. Charles RP, Iezza G, Amendola E, Dankort D, McMahon M. Mutationally activated BRAF(V600E) elicits papillary thyroid cancer in the adult mouse. Cancer Res 2011;71: 3863-71.
10. Wang J, Kobayashi T, Floc'h N, Kinkade CW, Aytes A, Dankort D, et al. B-Raf activation cooperates with PTEN loss to drive c-Myc expression in advanced prostate cancer. Cancer Res 2012;72: 4765-76.
11. Hruban RH, Goggins M, Parsons J, Kern SE. Progression model for pancreatic cancer. Clin Cancer Res 2000;6: 2969-72.
12. McBride KA, Ballinger ML, Killick E, Kirk J, Tattersall MH, Eeles RA, et al. Li-Fraumeni syndrome: Cancer risk assessment and clinical management. Nat Rev Clin Oncol 2014;11: 260-71.
13. Nichols KE, Malkin D, Garber JE, Fraumeni JF Jr, Li FP. Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiol Biomarkers Prev 2001;10: 83-7.
14. Jonkers J, Meuwissen R, van der GuldenH, Peterse H, van der Valk M, Berns A. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat Genet 2001;29: 418-25.
15. Aguirre AJ, Bardeesy N, Sinha M, Lopez L, Tuveson DA, Horner J, et al. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev 2003;17: 3112-26.
16. Jackson EL, Olive KP, Tuveson DA, Bronson R, Crowley D, Brown M, et al. The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res 2005;65: 10280-8.
17. Soriano P. Generalized lacZ expression with the ROSA26 Cre reporter strain. Nat Genet 1999;21: 70-1.
18. Wang X, Cunningham M, Zhang X, Tokarz S, Laraway B, Troxell M, et al. Phosphorylation regulates c-Myc's oncogenic activity in the mammary gland. Cancer Res 2011;71: 925-36.
19. Chapman HA, Li X, Alexander JP, Brumwell A, Lorizio W, Tan K, et al. Integrin alpha6beta4 identifies an adult distal lung epithelial population with regenerative potential in mice. J Clin Invest 2011;121: 2855-62.
20. Juan J, Muraguchi T, Iezza G, Sears RC, McMahon M. Diminished WNT → b-catenin → c-MYC signaling is a barrier for malignant progression of BRAFV600E-induced lung tumors. Genes Dev 2014;28: 561-75.
21. Raymond CS, Soriano P. High-efficiency FLP and PhiC31 site-specific recombination in mammalian cells. PLoS ONE 2007;2: E162.
22. Junttila MR, Karnezis AN, Garcia D, Madriles F, Kortlever RM, Rostker F, et al. Selective activation of p53-mediated tumour suppression in highgrade tumours. Nature 2010;468: 567-71.
23. Feldser DM, Kostova KK, Winslow MM, Taylor SE, Cashman C, Whittaker CA, et al. Stage-specific sensitivity to p53 restoration during lung cancer progression. Nature 2010;468: 572-5.
24. Zhu J, Woods D, McMahon M, Bishop JM. Senescence of human fibroblasts induced by oncogenic Raf. Genes Dev 1998;12: 2997-3007.
25. Ries S, Biederer C, Woods D, Shifman O, Shirasawa S, Sasazuki T, et al. Opposing effects of Ras on p53: Transcriptional activation of mdm2 and induction of p19ARF. Cell 2000;103: 321-30.
26. Lowe SW, Cepero E, Evan G. Intrinsic tumour suppression. Nature 2004;432: 307-15.
27. Minden A, Lin A, McMahon M, Lange-Carter C, Derijard B, Davis RJ, et al. Differential activation of ERK and JNK mitogen-activated protein kinases by Raf-1 and MEKK. Science 1994;266: 1719-23.
28. Lomax M, Fried M. Polyoma virus disrupts ARF signaling to p53. Oncogene 2001;20: 4951-60.
29. Trejo CL, Juan J, Vicent S, Sweet-Cordero A, McMahon M. MEK1/2 inhibition elicits regression of autochthonous lung tumors induced by KRASG12D or BRAFV600E. Cancer Res 2012;72: 3048-59.
30. Muzumdar MD, Tasic B, Miyamichi K, Li L, Luo L. A global doublefluorescent Cre reporter mouse. Genesis 2007;45: 593-605.
31. Vousden KH, Prives C. Blinded by the light: The growing complexity of p53. Cell 2009;137: 413-31.
32. Muller PA, Vousden KH. p53 mutations in cancer. Nat Cell Biol 2013;15: 2-8.
33. Goh AM, Coffill CR, Lane DP. The role of mutant p53 in human cancer. J Pathol 2011;223: 116-26.
34. Junttila MR, Evan GI. p53-A Jack of all trades but master of none. Nat Rev Cancer 2009;9: 821-9.
35. Christophorou MA, Martin-Zanca D, Soucek L, Lawlor ER, Brown-Swigart L, Verschuren EW, et al. Temporal dissection of p53 function in vitro and in vivo. Nat Genet 2005;37: 718-26.
36. Vassilev LT, Vu BT, Graves B, CarvajalD, Podlaski F, Filipovic Z, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004;303: 844-8.
37. Hikisz P, Kilianska ZM.PUMA, a critical mediator of cell death-one decade on from its discovery. Cell Mol Biol Lett 2012;17: 646-69.
38. Wang YF, Jiang CC, Kiejda KA, Gillespie S, Zhang XD, Hersey P. Apoptosis induction in human melanoma cells by inhibition of MEK is caspaseindependent and mediated by the Bcl-2 family members PUMA, Bim, and Mcl-1. Clin Cancer Res 2007;13: 4934-42.
39. Cartlidge RA, Thomas GR, Cagnol S, Jong K, Molton SA, Finch AJ, et al. Oncogenic BRAF(V600E) inhibits BIM expression to promote melanoma cell survival. Pigment Cell Melanoma Res 2008;21: 534-44.
40. Ley R, Ewings KE, Hadfield K, Cook SJ. Regulatory phosphorylation of Bim: Sorting out the ERK from the JNK. Cell Death Differ 2005;12: 1008-14.
41. Kracikova M, Akiri G, George A, Sachidanandam R, Aaronson SA. A threshold mechanism mediates p53 cell fate decision between growth arrest and apoptosis. Cell Death Differ 2013;20: 576-88.
42. HanahanD, Wagner EF, Palmiter RD. The origins of oncomice: A history of the first transgenic mice genetically engineered to develop cancer. Genes Dev 2007;21: 2258-70.
43. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005;8: 299-309.
44. Inoue M, Hager JH, Ferrara N, Gerber HP, Hanahan D. VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. Cancer Cell 2002;1: 193-202.
45. Jackson EL, Willis N, Mercer K, Bronson RT, Crowley D, Montoya R, et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 2001;15: 3243-8.
46. Dupuy AJ, Rogers LM, Kim J, Nannapaneni K, Starr TK, Liu P, et al. A modified sleeping beauty transposon system that can be used to model a wide variety of human cancers in mice. Cancer Res 2009;69: 8150-6.
47. Collisson EA, Trejo CL, Silva JM, Gu S, Korkola JE, Heiser LM, et al. A central role for RAF→MEK→ERK signaling in the genesis of pancreatic ductal adenocarcinoma. Cancer Discov 2012;2: 685-93.
48. Dankort D, Curley DP, Cartlidge RA, Nelson B, Karnezis AN, Damsky WE Jr., et al. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet 2009;41: 544-52.
49. Kamata T, Dankort D, Kang J, Giblett S, Pritchard CA, McMahon M, et al. Hematopoietic expression of oncogenic BRAF promotes aberrant growth of monocyte-lineage cells resistant to PLX4720. Mol Cancer Res 2013; 11: 1530-41.
50. Mito JK, Min HD, Ma Y, Carter JE, Brigman BE, Dodd L, et al. Oncogenedependent control of miRNA biogenesis and metastatic progression in a model of undifferentiated pleomorphic sarcoma. J Pathol 2012;229: 132-40.
51. Young NP, Crowley D, Jacks T. Uncoupling cancer mutations reveals critical timing of p53 loss in sarcomagenesis. Cancer Res 2011;71: 4040-7.
52. Bertwistle D, Sherr CJ. Regulation of the Arf tumor suppressor in Emicro-Myc transgenic mice: Longitudinal study of Myc-induced lymphomagenesis. Blood 2007;109: 792-4.
53. Burd CE, Sorrentino JA, Clark KS, Darr DB, Krishnamurthy J, Deal AM, et al. Monitoring tumorigenesis and senescence in vivo with a p16(INK4a)-luciferase model. Cell 2013;152: 340-51.
54. Huillard E, Hashizume R, Phillips JJ, Griveau A, Ihrie RA, Aoki Y, et al. Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy. Proc Natl Acad Sci U S A 2012;109: 8710-5.